APA (7th ed.) Citation

O, E., JH, S., AG, Y., CJ, T., JS, C., DJ, L., . . . SK, B. (2025). Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA dermatology, 161(6), 656. https://doi.org/10.1001/jamadermatol.2025.0251

Chicago Style (17th ed.) Citation

O, Elghawy, et al. "Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome." JAMA Dermatology 161, no. 6 (2025): 656. https://doi.org/10.1001/jamadermatol.2025.0251.

MLA (9th ed.) Citation

O, Elghawy, et al. "Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome." JAMA Dermatology, vol. 161, no. 6, 2025, p. 656, https://doi.org/10.1001/jamadermatol.2025.0251.